Saint-Herblain (France), October 27, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe.
Valneva will host moderated “fireside chat” presentations to discuss the Company’s key value drivers and upcoming catalysts, primarily the upcoming Phase 3 trial outcomes for VLA15, the Company’s Lyme disease vaccine candidate, which is partnered with Pfizer. If successful, Pfizer aims to submit applications for U.S. and European market authorization in 2026. Pending approval, Valneva expects Pfizer to launch the vaccine in the second half of 2027.
Guggenheim 2nd Annual Healthcare Innovation Conference
Date/Time: November 10, 10:30am EST
Format: Fireside chat and investor meetings
Location: Boston, Massachusetts
Stifel 2025 Healthcare Conference
Date/Time: November 11, 9:20am EST
Format: Fireside chat and investor meetings
Location: New York, New York
Jefferies London Healthcare Conference
Date/Time: November 19, 2:00pm GMT
Format: Fireside chat and investor meetings
Location: London, United Kingdom
Webcast Link: https://wsw.com/webcast/jeff332/vla/1693849
A replay of the webcast will be available following the live events in the “Investor” section of the Valneva website at www.valneva.com.
Institutional investors who would like to meet with Valneva management at any of the below conferences are asked to submit a request to their representative at the respective bank.
To access the full release, please click on the PDF below.